Medscape is available in 5 Language Editions – Choose your Edition here.


Dermatologic Manifestations of Sebaceous Carcinoma

  • Author: Wesley Wu, MD; Chief Editor: Dirk M Elston, MD  more...
Updated: Apr 15, 2016


Sebaceous gland carcinoma is an aggressive, uncommon, cutaneous tumor first well-described by Allaire in 1891.[1] This tumor is thought to arise from sebaceous glands in the skin and, thus, may arise anywhere on the body where these glands exist, including the genitalia.[2, 3, 4, 5] Approximately 75% of these tumors arise in the periocular region, an area rich in a variety of types of sebaceous glands.[6, 7] This tumor exhibits an aggressive clinical course, with a significant tendency for both local recurrence and distant metastasis.

Diagnosis and therapy tend to be delayed because sebaceous carcinoma is frequently mistaken for more common benign entities, further complicating treatment of this aggressive malignancy.[8, 9, 10, 11] In addition, a varied histologic appearance may occur, and delayed diagnosis or misdiagnosis following a biopsy is not uncommon.[8, 9, 10]

When arising in the periocular region, the clinical presentation is often variable, and sebaceous gland carcinoma is often not initially suspected. Instead, patients may receive multiple courses of incision and drainage for chalazion before a definitive biopsy is performed.[8, 12, 13]

Most sebaceous gland carcinomas have no obvious etiology. Only a few are associated with Muir-Torre syndrome. Although sebaceous adenoma and epithelioma are more specific markers for Muir-Torre syndrome, an evaluation for this syndrome is advisable once sebaceous gland carcinoma is diagnosed.[14] In approximately 40% of cases, patients with Muir-Torre syndrome develop some type of sebaceous tumor before or concurrent with visceral malignancy.[15]



Sebaceous gland carcinoma resembles normal sebaceous glands.[16] One may reasonably speculate that sebaceous gland carcinoma arises from mature sebaceous glands. Histologic studies have suggested that periocular sebaceous gland carcinomas arise from the sebaceous glands in this region. The following 5 types of sebaceous glands are seen in the periocular region[6, 7] :

  • Meibomian glands of the tarsal plate
  • Glands of Zeis of the cilia
  • Sebaceous glands of the eyebrows
  • Glands of the caruncle
  • Glands of the fine hair follicles of the eyelid surface

In one histologic series, 51% of cases reportedly arose from a specialized sebaceous gland of the eyelid, the meibomian gland. Indeed, sebaceous gland carcinoma is sometimes referred to as meibomian gland carcinoma. In the same series, 10% of cases arose from the glands of Zeis, less than 10% of cases arose from the caruncle and the eyebrow each, and 12% were multicentric with no obvious source of origin.[17]

Isolated case reports describe sebaceous gland carcinoma limited to the epithelium, with no obvious connection to the underlying sebaceous glands.[18] In these rare cases, the sebaceous gland carcinoma may fill the conjunctival epithelium and create the appearance of squamous cell carcinoma in situ. Whether these tumors truly have an epithelial origin or whether the dermal connection has been lost or is simply unappreciated is unknown.

Approximately 30 case reports have described the development of sebaceous carcinoma in a sebaceous nevus of Jadassohn.[19, 20, 21, 22, 23, 24] Sebaceous carcinoma arising from a nevus sebaceous is more common in women and elderly persons, described as a nodule or ulcerated tumor that usually demonstrates rapid growth prior to diagnosis.[21] Although generally larger in diameter, this distinct entity tends to possess more benign features and follow a more favorable course.[25] Controversy exists regarding the prophylactic removal of a nevus sebaceous, but when malignant neoplasms are suspected, removal is warranted regardless.[26]

Recently, several molecular markers have been identified that may help elucidate the pathophysiologic progression of sebaceous carcinoma. Promotion of tumor metastasis and a poor clinical outcome have been associated with epigenetic inactivation of E-cadherin and subsequent loss of cell-to-cell adhesion in sebaceous carcinoma.[27] Hormonal receptors may also play a significant role. Increased expression of androgen receptor in the nucleus of periocular sebaceous carcinoma may indicate a greater likelihood of recurrence and help distinguish this entity from squamous cell and basal cell carcinomas.[28, 29] In addition, HER2 gene amplification and protein overexpression have been demonstrated in sebaceous carcinoma and may serve as potential therapeutic targets.[30] Future studies are needed to further clarify these mechanisms.




United States

Sebaceous gland carcinoma is a rare tumor. Approximately 75% of sebaceous gland carcinomas occur in the periocular region.[6] In this region, sebaceous gland carcinoma represents 1-5.5% of eyelid malignancies, fourth after basal cell carcinoma, squamous cell carcinoma, and melanoma.[17, 31, 32]


Sebaceous gland carcinoma seems to occur with greater frequency relative to other skin cancers in Asian populations. In a large retrospective series from China, sebaceous gland carcinoma was the second most common periocular tumor after basal cell carcinoma, reported to represent 33% of eyelid malignancies.[32]


Women tend to be affected somewhat more often than men, with 57-77% of patients being women in several large series.[8, 16, 17, 33, 34, 35]


Most patients present in their sixth or seventh decade of life, although the range is from early childhood through the nineties.[16, 36] The youngest reported case arose in a 3-year-old child.[37]



Sebaceous gland carcinoma is an aggressive tumor, with a tendency for both local recurrence and distant metastasis. Reported local recurrence rates range from 9-36%, with larger series reporting recurrence rates in the 30% range. Local recurrence tends to occur within 5 years.[6, 10]

The rate of metastasis in extraocular and ocular sebaceous carcinoma is thought to be similar, occurring in 14-25% of cases, first to the draining lymph nodes and then to distant sites.[8, 17, 38] Sites of distant metastasis include the liver, lungs, bones, and brain.[8, 17, 39] Nodal metastasis has not been shown to be an independent prognostic factor in sebaceous carcinoma.[40]  Metastasis has been reported to occur as late as 5 years after the initial diagnosis, lending support to the continual surveillance of patients with sebaceous carcinoma.34 

Reported clinicopathological features associated with a poor prognosis include orbital invasion, upper and lower eyelid involvement, poor differentiation,[41] lacrimal gland involvement,[41] tumor diameter greater than 10 mm,[42] pagetoid spread, and symptom duration greater than 6 months.[17] Patients aged 80 years or older at the time of diagnosis may also have reduced 5-year-disease specific survival.[40]

One Korean study of 40 patients found that T staging by the American Joint Committee on Cancer (AJCC) yielded important prognostic value and that patients with sebaceous carcinoma of at least stage T2b (>10 mm in size or involving full-thickness eyelid) had an increased rate of metastasis.[43] Another study of 50 patients reported an AJCC stage T3a (>20 mm in size, invasion of adjacent ocular or orbital structures, or perineural invasion) was correlated with distant metastasis and death from disease.[44] A 2016 study of 191 patients found that orbital tumor extension and perivascular invasion was associated with systemic metastasis, but only orbital tumor extension correlated with death due to systemic metastasis.[45]

The 5-year mortality rate for patients with metastatic disease is reportedly 71.1% (standard error, 1.5%) and the 10-year survival rate is 45.9% (standard error, 2.1%).[46]

Contributor Information and Disclosures

Wesley Wu, MD Resident Physician, Department of Dermatology, Baylor College of Medicine

Wesley Wu, MD is a member of the following medical societies: American Academy of Dermatology, American Society for Dermatologic Surgery, Society for Pediatric Dermatology

Disclosure: Nothing to disclose.


Mohsin R Mir, MD Director, High Risk Skin Cancer Clinic, Assistant Professor, Mohs Surgery, Laser and Cosmetic Surgery, Department of Dermatology, Baylor College of Medicine

Mohsin R Mir, MD is a member of the following medical societies: American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery

Disclosure: Nothing to disclose.

Specialty Editor Board

Richard P Vinson, MD Assistant Clinical Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine; Consulting Staff, Mountain View Dermatology, PA

Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Texas Medical Association, Association of Military Dermatologists, Texas Dermatological Society

Disclosure: Nothing to disclose.

John G Albertini, MD Private Practice, The Skin Surgery Center; Clinical Associate Professor (Volunteer), Department of Plastic and Reconstructive Surgery, Wake Forest University School of Medicine; President-Elect, American College of Mohs Surgery

John G Albertini, MD is a member of the following medical societies: American Academy of Dermatology, American College of Mohs Surgery

Disclosure: Received grant/research funds from Genentech for investigator.

Chief Editor

Dirk M Elston, MD Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Additional Contributors

Kelly M Cordoro, MD Assistant Professor of Clinical Dermatology and Pediatrics, Department of Dermatology, University of California, San Francisco School of Medicine

Kelly M Cordoro, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, Medical Society of Virginia, Society for Pediatric Dermatology, Women's Dermatologic Society, Association of Professors of Dermatology, National Psoriasis Foundation, Dermatology Foundation

Disclosure: Nothing to disclose.


Amy Lynn Basile, DO, MPH Sun Coast Hospital/Largo Medical Center, Largo, Florida

Amy Lynn Basile, DO, MPH is a member of the following medical societies: American Medical Association, American Osteopathic Association, and American Osteopathic College of Dermatology

Disclosure: Nothing to disclose.

James M Spencer, MD Professor of Clinical Dermatology, Mount Sinai School of Medicine, New York; Private Practice, Spencer Dermatology, St Petersburg, Florida

James M Spencer, MD is a member of the following medical societies: American Academy of Cosmetic Surgery, American Academy of Dermatology, American College of Mohs Micrographic Surgery and Cutaneous Oncology, American Dermatological Association, American Medical Association, American Society for Dermatologic Surgery, American Society for Laser Medicine and Surgery, and International Society for Dermatologic Surgery

Disclosure: Graceway Pharmaceutical Honoraria Speaking and teaching; Sanofi Aventis Honoraria Consulting; Medicis Grant/research funds Independent contractor; Peplin Grant/research funds Independent contractor; Leo Pharmicuticals Honoraria Board membership

  1. Kass LG, Hornblass A. Sebaceous carcinoma of the ocular adnexa. Surv Ophthalmol. 1989 May-Jun. 33(6):477-90. [Medline].

  2. Gomes CC, Lacerda JC, Pimenta FJ, do Carmo MA, Gomez RS. Intraoral sebaceous carcinoma. Eur Arch Otorhinolaryngol. 2007 Jul. 264(7):829-32. [Medline].

  3. Jacobs DM, Sandles LG, Leboit PE. Sebaceous carcinoma arising from Bowen's disease of the vulva. Arch Dermatol. 1986 Oct. 122(10):1191-3. [Medline].

  4. Tan O, Ergen D, Arslan R. Sebaceous carcinoma on the scalp. Dermatol Surg. 2006 Oct. 32(10):1290-3. [Medline].

  5. Pusiol T, Morichetti D, Zorzi MG. Sebaceous carcinoma of the vulva: critical approach to grading and review of the literature. Pathologica. 2011 Jun. 103(3):64-7. [Medline].

  6. Nelson BR, Hamlet KR, Gillard M, Railan D, Johnson TM. Sebaceous carcinoma. J Am Acad Dermatol. 1995 Jul. 33(1):1-15; quiz 16-8. [Medline].

  7. Shields JA, Demirci H, Marr BP, Eagle RC Jr, Shields CL. Sebaceous carcinoma of the ocular region: a review. Surv Ophthalmol. 2005 Mar-Apr. 50(2):103-22. [Medline].

  8. Doxanas MT, Green WR. Sebaceous gland carcinoma. Review of 40 cases. Arch Ophthalmol. 1984 Feb. 102(2):245-9. [Medline].

  9. Khan JA, Grove AS Jr, Joseph MP, Goodman M. Sebaceous carcinoma. Diuretic use, lacrimal system spread, and surgical margins. Ophthal Plast Reconstr Surg. 1989. 5(4):227-34. [Medline].

  10. Song A, Carter KD, Syed NA, Song J, Nerad JA. Sebaceous cell carcinoma of the ocular adnexa: clinical presentations, histopathology, and outcomes. Ophthal Plast Reconstr Surg. 2008 May-Jun. 24(3):194-200. [Medline].

  11. Wolfe JT 3rd, Yeatts RP, Wick MR, Campbell RJ, Waller RR. Sebaceous carcinoma of the eyelid. Errors in clinical and pathologic diagnosis. Am J Surg Pathol. 1984 Aug. 8(8):597-606. [Medline].

  12. Pang P, Rodriguez-Sains RS. Ophthalmologic oncology: sebaceous carcinomas of the eyelids. J Dermatol Surg Oncol. 1985 Mar. 11(3):260-4. [Medline].

  13. Sung D, Kaltreider SA, Gonzalez-Fernandez F. Early onset sebaceous carcinoma. Diagn Pathol. 2011 Sep 5. 6:81. [Medline]. [Full Text].

  14. Schwartz RA, Torre DP. The Muir-Torre syndrome: a 25-year retrospect. J Am Acad Dermatol. 1995 Jul. 33(1):90-104. [Medline].

  15. Schwartz RA, Torre DP. The Muir-Torre syndrome: a 25-year retrospect. J Am Acad Dermatol. 1995 Jul. 33(1):90-104. [Medline].

  16. Pang P, Rodriguez-Sains RS. Ophthalmologic oncology: sebaceous carcinomas of the eyelids. J Dermatol Surg Oncol. 1985 Mar. 11(3):260-4. [Medline].

  17. Rao NA, Hidayat AA, McLean IW, Zimmerman LE. Sebaceous carcinomas of the ocular adnexa: A clinicopathologic study of 104 cases, with five-year follow-up data. Hum Pathol. 1982 Feb. 13(2):113-22. [Medline].

  18. Beach A, Severance AO. Sebaceous gland Carcinoma. Ann Surg. 1942 Feb. 115(2):258-66. [Medline].

  19. Arshad AR, Azman WS, Kreetharan A. Solitary sebaceous nevus of Jadassohn complicated by squamous cell carcinoma and basal cell carcinoma. Head Neck. 2008 Apr. 30(4):544-8. [Medline].

  20. Duncan A, Wilson N, Leonard N. Squamous cell carcinoma developing in a naevus sebaceous of Jadassohn. Am J Dermatopathol. 2008 Jun. 30(3):269-70. [Medline].

  21. Kazakov DV, Calonje E, Zelger B, et al. Sebaceous carcinoma arising in nevus sebaceus of Jadassohn: a clinicopathological study of five cases. Am J Dermatopathol. 2007 Jun. 29(3):242-8. [Medline].

  22. Matsuda K, Doi T, Kosaka H, Tasaki N, Yoshioka H, Kakibuchi M. Sebaceous carcinoma arising in nevus sebaceus. J Dermatol. 2005 Aug. 32(8):641-4. [Medline].

  23. Miller CJ, Ioffreda MD, Billingsley EM. Sebaceous carcinoma, basal cell carcinoma, trichoadenoma, trichoblastoma, and syringocystadenoma papilliferum arising within a nevus sebaceus. Dermatol Surg. 2004 Dec. 30(12 Pt 2):1546-9. [Medline].

  24. Wang E, Lee JS, Kazakov DV. A rare combination of sebaceoma with carcinomatous change (sebaceous carcinoma), trichoblastoma, and poroma arising from a nevus sebaceus. J Cutan Pathol. 2013 Jul. 40(7):676-82. [Medline].

  25. Izumi M, Tang X, Chiu CS, Nagai T, Matsubayashi J, Iwaya K. Ten cases of sebaceous carcinoma arising in nevus sebaceus. J Dermatol. 2008 Nov. 35(11):704-11. [Medline].

  26. Barkham MC, White N, Brundler MA, Richard B, Moss C. Should naevus sebaceus be excised prophylactically? A clinical audit. J Plast Reconstr Aesthet Surg. 2007. 60(11):1269-70. [Medline].

  27. Jayaraj P, Sen S, Sharma A, Chosdol K, Kashyap S, Rai A. Epigenetic inactivation of the E-cadherin gene in eyelid sebaceous gland carcinoma. Br J Dermatol. 2012 Sep. 167(3):583-90. [Medline].

  28. Mulay K, Shah SJ, Aggarwal E, White VA, Honavar SG. Periocular sebaceous gland carcinoma: do androgen receptor (NR3C4) and nuclear survivin (BIRC5) have a prognostic significance?. Acta Ophthalmol. 2014 Dec. 92(8):e681-7. [Medline].

  29. Mulay K, White VA, Shah SJ, Honavar SG. Sebaceous carcinoma: clinicopathologic features and diagnostic role of immunohistochemistry (including androgen receptor). Can J Ophthalmol. 2014 Aug. 49(4):326-32. [Medline].

  30. Kwon MJ, Shin HS, Nam ES, Cho SJ, Lee MJ, Lee S. Comparison of HER2 gene amplification and KRAS alteration in eyelid sebaceous carcinomas with that in other eyelid tumors. Pathol Res Pract. 2014 Oct 27. [Medline].

  31. Kwitko ML, Boniuk M, Zimmerman LE. Eyelid tumors with reference to lesions confused with squamous cell carcinoma. I. Incidence and errors in diagnosis. Arch Ophthalmol. 1963 Jun. 69:693-7. [Medline].

  32. Ni C, Searl SS, Kuo PK, Chu FR, Chong CS, Albert DM. Sebaceous cell carcinomas of the ocular adnexa. Int Ophthalmol Clin. 1982 Spring. 22(1):23-61. [Medline].

  33. Callahan EF, Appert DL, Roenigk RK, Bartley GB. Sebaceous carcinoma of the eyelid: a review of 14 cases. Dermatol Surg. 2004 Aug. 30(8):1164-8. [Medline].

  34. Ni C, Guo BK. Pathologic classification of meibomian gland carcinomas of eyelids: clinical and pathologic study of 156 cases. Chin Med J (Engl). 1979 Oct. 92(10):671-6. [Medline].

  35. Shields JA, Demirci H, Marr BP, Eagle RC Jr, Stefanyszyn M, Shields CL. Conjunctival epithelial involvement by eyelid sebaceous carcinoma. The 2003 J. Howard Stokes lecture. Ophthal Plast Reconstr Surg. 2005 Mar. 21(2):92-6. [Medline].

  36. Justi RA. Sebaceous carcinoma; report of case developing in area of radiodermatitis. AMA Arch Derm. 1958 Feb. 77(2):195-200. [Medline].

  37. Hagedorn A. Adenocarcinoma of a meibomian gland. Arch Ophthalmol. 1934. 6:850-67.

  38. Berlin AL, Amin SP, Goldberg DJ. Extraocular sebaceous carcinoma treated with Mohs micrographic surgery: report of a case and review of literature. Dermatol Surg. 2008 Feb. 34(2):254-7. [Medline].

  39. Husain A, Blumenschein G, Esmaeli B. Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid. Int J Dermatol. 2008 Mar. 47(3):276-9. [Medline].

  40. Thomas WW, Fritsch VA, Lentsch EJ. Population-based analysis of prognostic indicators in sebaceous carcinoma of the head and neck. Laryngoscope. 2013 Sep. 123(9):2165-9. [Medline].

  41. Yoon JS, Kim SH, Lee CS, Lew H, Lee SY. Clinicopathological analysis of periocular sebaceous gland carcinoma. Ophthalmologica. 2007. 221(5):331-9. [Medline].

  42. Saito A, Tsutsumida A, Furukawa H, Saito N, Yamamoto Y. Sebaceous carcinoma of the eyelids: a review of 21 cases. J Plast Reconstr Aesthet Surg. 2008 Nov. 61(11):1328-31. [Medline].

  43. Choi YJ, Jin HC, Lee MJ, Kim N, Choung HK, Khwarg SI. Prognostic value of clinical and pathologic T stages defined by the American Joint Committee on Cancer for eyelid sebaceous carcinoma in Korea. Jpn J Ophthalmol. 2014 Jul. 58(4):327-33. [Medline].

  44. Esmaeli B, Nasser QJ, Cruz H, Fellman M, Warneke CL, Ivan D. American Joint Committee on Cancer T category for eyelid sebaceous carcinoma correlates with nodal metastasis and survival. Ophthalmology. 2012 May. 119 (5):1078-82. [Medline].

  45. Kaliki S, Gupta A, Ali MH, Ayyar A, Naik MN. Prognosis of eyelid sebaceous gland carcinoma based on the tumor (T) category of the American Joint Committee on Cancer (AJCC) classification. Int Ophthalmol. 2016 Feb 1. [Medline].

  46. Dasgupta T, Wilson LD, Yu JB. A retrospective review of 1349 cases of sebaceous carcinoma. Cancer. 2009 Jan 1. 115 (1):158-65. [Medline].

  47. Kitagawa H, Mizuno M, Nakamura Y, Kurokawa I, Mizutani H. Cutaneous horn can be a clinical manifestation of underlying sebaceous carcinoma. Br J Dermatol. 2007 Jan. 156(1):180-2. [Medline].

  48. Wick MR, Goellner JR, Wolfe JT 3rd, Su WP. Adnexal carcinomas of the skin. II. Extraocular sebaceous carcinomas. Cancer. 1985 Sep 1. 56(5):1163-72. [Medline].

  49. Altemani A, Vargas PA, Cardinali I, et al. Sebaceous carcinoma of the parotid gland in children: an immunohistochemical and ploidy study. Int J Oral Maxillofac Surg. 2008 May. 37(5):433-40. [Medline].

  50. El Demellawy D, Escott N, Salama S, Alowami S. Sebaceoma of the external ear canal: an unusual location. Case report and review of the literature. J Cutan Pathol. 2008 Oct. 35(10):963-6. [Medline].

  51. Alzaraa A, Ghafoor I, Yates A, Dhebri A. Sebaceous carcinoma of the skin of the breast: a case report. J Med Case Reports. 2008 Aug 15. 2:276. [Medline].

  52. Cibull TL, Thomas AB, Badve S, Billings SD. Sebaceous carcinoma of the nipple. J Cutan Pathol. 2008 Jun. 35(6):608-10. [Medline].

  53. Coates D, Bowling J, Haskett M. Dermoscopic features of extraocular sebaceous carcinoma. Australas J Dermatol. 2011 Aug. 52 (3):212-3. [Medline].

  54. Schlernitzauer DA, Font RL. Sebaceous gland carcinoma of the eyelid. Arch Ophthalmol. 1976 Sep. 94(9):1523-5. [Medline].

  55. Becker-Schiebe M, Hannig H, Hoffmann W, Donhuijsen K. Muir-Torre syndrome - an uncommon localization of sebaceous carcinomas following irradiation. Acta Oncol. 2012 Feb. 51 (2):265-8. [Medline].

  56. Hayashi N, Furihata M, Ohtsuki Y, Ueno H. Search for accumulation of p53 protein and detection of human papillomavirus genomes in sebaceous gland carcinoma of the eyelid. Virchows Arch. 1994. 424(5):503-9. [Medline].

  57. Gonzalez-Fernandez F, Kaltreider SA, Patnaik BD, et al. Sebaceous carcinoma. Tumor progression through mutational inactivation of p53. Ophthalmology. 1998 Mar. 105(3):497-506. [Medline].

  58. Landis MN, Davis CL, Bellus GA, Wolverton SE. Immunosuppression and sebaceous tumors: a confirmed diagnosis of Muir-Torre syndrome unmasked by immunosuppressive therapy. J Am Acad Dermatol. 2011 Nov. 65(5):1054-1058.e1. [Medline].

  59. Seo BF, Jung HW, Choi IK, Rhie JW. Sebaceous carcinoma of the suprapubic area in a liver transplant recipient. Ann Dermatol. 2014 Jun. 26 (3):395-8. [Medline].

  60. Levi Z, Hazazi R, Kedar-Barnes I, Hodak E, Gal E, Mor E, et al. Switching from tacrolimus to sirolimus halts the appearance of new sebaceous neoplasms in Muir-Torre syndrome. Am J Transplant. 2007 Feb. 7 (2):476-9. [Medline].

  61. Chang TW, Weaver AL, Brewer JD. Sebaceous carcinoma in the clinical setting of non-Hodgkin lymphoma: the Mayo Clinic experience. Int J Dermatol. 2013 Oct. 52(10):1210-4. [Medline].

  62. Reina RS, Parry E. Aggressive extraocular sebaceous carcinoma in a 52-year-old man. Dermatol Surg. 2006 Oct. 32 (10):1283-6. [Medline].

  63. Herceg D, Kusacić-Kuna S, Dotlić S, Petrović R, Bracić I, Horvatić Herceg G, et al. F-18 FDG PET evaluation of a rapidly growing extraocular sebaceous carcinoma. Clin Nucl Med. 2009 Nov. 34 (11):798-801. [Medline].

  64. Orcurto A, Gay BE, Sozzi WJ, Gilliet M, Leyvraz S. Long-Term Remission of an Aggressive Sebaceous Carcinoma following Chemotherapy. Case Rep Dermatol. 2014 Jan. 6 (1):80-4. [Medline].

  65. Chang AY, Miller CJ, Elenitsas R, Newman JG, Sobanko JF. Management Considerations in Extraocular Sebaceous Carcinoma. Dermatol Surg. 2016 Jan. 42 Suppl 1:S57-65. [Medline].

  66. Roberts ME, Riegert-Johnson DL, Thomas BC, Rumilla KM, Thomas CS, Heckman MG. A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir-Torre variant of Lynch syndrome. Genet Med. 2014 Sep. 16(9):711-6. [Medline].

  67. Boennelycke M, Thomsen BM, Holck S. Sebaceous neoplasms and the immunoprofile of mismatch-repair proteins as a screening target for syndromic cases. Pathol Res Pract. 2014 Oct 23. [Medline].

  68. Perera S, Ramyar L, Mitri A, Pollett A, Gallinger S, Speevak MD, et al. A novel complex mutation in MSH2 contributes to both Muir-Torre and Lynch Syndrome. J Hum Genet. 2010 Jan. 55 (1):37-41. [Medline].

  69. John AM, Schwartz RA. Muir-Torre syndrome (MTS): An update and approach to diagnosis and management. J Am Acad Dermatol. 2016 Mar. 74 (3):558-66. [Medline].

  70. Nemoto Y, Arita R, Mizota A, Sasajima Y. Differentiation between chalazion and sebaceous carcinoma by noninvasive meibography. Clin Ophthalmol. 2014. 8:1869-75. [Medline].

  71. Harvey JT, Anderson RL. The management of meibomian gland carcinoma. Ophthalmic Surg. 1982 Jan. 13(1):56-61. [Medline].

  72. Hood IC, Qizilbash AH, Salama SS, Young JE, Archibald SD. Needle aspiration cytology of sebaceous carcinoma. Acta Cytol. 1984 May-Jun. 28(3):305-12. [Medline].

  73. Maheshwari R, Maheshwari S, Shekde S. Role of fine needle aspiration cytology in diagnosis of eyelid sebaceous carcinoma. Indian J Ophthalmol. 2007 May-Jun. 55(3):217-9. [Medline].

  74. Goyal S, Honavar SG, Naik M, Vemuganti GK. Fine needle aspiration cytology in diagnosis of metastatic sebaceous gland carcinoma of the eyelid to the lymph nodes with clinicopathological correlation. Acta Cytol. 2011. 55(5):408-12. [Medline].

  75. Putterman AM. Conjunctival map biopsy to determine pagetoid spread. Am J Ophthalmol. 1986 Jul 15. 102(1):87-90. [Medline].

  76. Rapini RP. Sebaceous Neoplasms. Practical Dermatopathology. Elsevier Inc; 2005. 283-4.

  77. Plaza JA, Mackinnon A, Carrillo L, Prieto VG, Sangueza M, Suster S. Role of immunohistochemistry in the diagnosis of sebaceous carcinoma: a clinicopathologic and immunohistochemical study. Am J Dermatopathol. 2015 Nov. 37 (11):809-21. [Medline].

  78. Bolognia JL, Jorizzo JL, Rapini RP. Sebaceous Carcinoma. Callen JP, Horn TD, Mancini AJ, Salasche SJ, Schaffer JV, Schwarz T, Stingl G, Stone MS, eds. Dermatology. 2nd ed. Amsterdam: Elsevier; 2008. 1703.

  79. Nunery WR, Welsh MG, McCord CD Jr. Recurrence of sebaceous carcinoma of the eyelid after radiation therapy. Am J Ophthalmol. 1983 Jul. 96(1):10-5. [Medline].

  80. Yen MT, Tse DT, Wu X, Wolfson AH. Radiation therapy for local control of eyelid sebaceous cell carcinoma: report of two cases and review of the literature. Ophthal Plast Reconstr Surg. 2000 May. 16(3):211-5. [Medline].

  81. Orcurto A, Gay BE, Sozzi WJ, Gilliet M, Leyvraz S. Long-Term Remission of an Aggressive Sebaceous Carcinoma following Chemotherapy. Case Rep Dermatol. 2014 Jan. 6(1):80-4. [Medline].

  82. Paschal BR, Bagley CS. Sebaceous gland carcinoma of the eyelid: complete response to sequential combination chemotherapy. N C Med J. 1985 Sep. 46(9):473-4. [Medline].

  83. Priyadarshini O, Biswas G, Biswas S, Padhi R, Rath S. Neoadjuvant chemotherapy in recurrent sebaceous carcinoma of eyelid with orbital invasion and regional lymphadenopathy. Ophthal Plast Reconstr Surg. 2010 Sep-Oct. 26(5):366-8. [Medline].

  84. Murthy R, Honavar SG, Burman S, Vemuganti GK, Naik MN, Reddy VA. Neoadjuvant chemotherapy in the management of sebaceous gland carcinoma of the eyelid with regional lymph node metastasis. Ophthal Plast Reconstr Surg. 2005 Jul. 21(4):307-9. [Medline].

  85. Spencer JM, Nossa R, Tse DT, Sequeira M. Sebaceous carcinoma of the eyelid treated with Mohs micrographic surgery. J Am Acad Dermatol. 2001 Jun. 44(6):1004-9. [Medline].

  86. Snow SN, Larson PO, Lucarelli MJ, Lemke BN, Madjar DD. Sebaceous carcinoma of the eyelids treated by mohs micrographic surgery: report of nine cases with review of the literature. Dermatol Surg. 2002 Jul. 28(7):623-31. [Medline].

  87. Hou JL, Killian JM, Baum CL, Otley CC, Roenigk RK, Arpey CJ. Characteristics of sebaceous carcinoma and early outcomes of treatment using Mohs micrographic surgery versus wide local excision: an update of the Mayo Clinic experience over the past 2 decades. Dermatol Surg. 2014 Mar. 40(3):241-6. [Medline].

  88. Folberg R, Whitaker DC, Tse DT, Nerad JA. Recurrent and residual sebaceous carcinoma after Mohs' excision of the primary lesion. Am J Ophthalmol. 1987 Jun 15. 103(6):817-23. [Medline].

  89. While B, Salvi S, Currie Z, Mudhar HS, Tan JH. Excision and delayed reconstruction with paraffin section histopathological analysis for periocular sebaceous carcinoma. Ophthal Plast Reconstr Surg. 2014 Mar-Apr. 30(2):105-9. [Medline].

  90. Sawyer AR, McGoldrick RB, Mackey S, Powell B, Pohl M. Should extraocular sebaceous carcinoma be investigated using sentinel node biopsy?. Dermatol Surg. 2009 Apr. 35(4):704-8. [Medline].

  91. Tryggvason G, Bayon R, Pagedar NA. Epidemiology of sebaceous carcinoma of the head and neck: implications for lymph node management. Head Neck. 2012 Dec. 34(12):1765-8. [Medline].

  92. Tryggvason G, Bayon R, Pagedar NA. Epidemiology of sebaceous carcinoma of the head and neck: implications for lymph node management. Head Neck. 2012 Dec. 34 (12):1765-8. [Medline].

Irregular lobules and sheets of atypical sebaceous cells (20x magnification).
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.